SEC Form 4 · accession 0000919574-15-008535
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 2, 2015
Accepted (ET)
Dec 4, 2015 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF2,F1 | $5.2123 | Dec 2, 2015 | P | 34,647 | A | — | Aug 28, 2019 | Common Stock | 34,647 | 34,647 | I |
| WarrantF2,F1 | $3.58 | Dec 2, 2015 | P | 38,805 | A | — | Apr 29, 2020 | Common Stock | 38,805 | 889,403 | I |
Explanation of responses
- F1These warrants are currently exercisable.
- F2These warrants are owned directly by CDK Associates, LLC, which is a reporting person. The warrants directly owned by CDK Associates, LLC may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each of Caxton Corporation and Bruce Kovner disclaims beneficial ownership of these warrants except to the extent of its or his pecuniary interest therein, and the inclusion of these warrants in this report shall not be deemed to be an admission of the beneficial ownership of all of the reported warrants for purposes of Section 16 or for any other purpose.
Remarks
Scott Morenstein, a director of the Issuer, is an employee of Caxton Alternative Management LP, an affiliate of Caxton Corporation.